drug-reactions
Can spatial proteomics find a TEN therapy?
Open access · cc by · source: Europe PMC
Deep visual proteomics of drug-reaction skin (>5,000 proteins/cell type) revealed interferon–STAT1 programs in TEN; JAK inhibitors improved disease in mouse models.
Key findings
TEN showed enriched type I/II interferon signatures and phosphorylated STAT1. Tofacitinib, baricitinib, abrocitinib, or upadacitinib ameliorated clinical/histological severity in mice. TEN involves >30% epidermal detachment and lacked effective therapy.
Methodology
Used deep visual proteomics on archived FFPE biopsies across CADR severities to quantify keratinocyte and immune-cell proteomes, then tested oral JAKis in two TEN mouse models.
Limitations
Mouse efficacy and proteomic nomination are not a completed large randomized TEN trial; dosing/safety in critically ill TEN patients need careful clinical evaluation.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.